Table 5 Prevalence of the four most commonly used primary sedatives and drugs with sedation as a prominent adverse effect/containing a sedating component among residential care home residents with dementia
From: Sedative load of medications prescribed for older people with dementia in care homes
Variable | Drug Name | All residents | Care Home | |||||
|---|---|---|---|---|---|---|---|---|
| Â | Â | Â | 1 | 2 | 3 | 4 | 5 | 6 |
| Â | Â | n = 115 | n = 20 | n = 17 | n = 14 | n = 22 | n = 30 | n = 12 |
Baseline | Â | Â | Â | Â | Â | Â | Â | Â |
Primary Sedatives [no.(%)] | Promazine | 5 (4.4) | 2 (10.0) | 0 | 1 (7.1) | 1 (4.5) | 1 (3.3) | 0 |
| Â | Temazepam | 4 (3.5) | 0 | 0 | 1 (7.1) | 1 (4.5) | 0 | 1 (8.3) |
| Â | Lorazepam | 3 (2.6) | 0 | 1 (5.9) | 1 (7.1) | 1 (4.5) | 0 | 0 |
| Â | Amitriptyline | 3 (2.6) | 2 (10.0) | 1 (5.9) | 0 | 0 | 0 | 0 |
Drugs with sedation as a prominent adverse effect/ | Citalopram | 18 (15.7) | 6 (30.0) | 2 (11.8) | 1 (7.1) | 1 (4.5) | 5 (16.7) | 3 (25.0) |
containing a sedating component [no.(%)] | Quetiapine | 14 (12.2) | 0 | 6 (35.3) | 1 (7.1) | 5 (22.7) | 1 (3.3) | 1 (8.3) |
| Â | Trazodone | 12 (10.4) | 0 | 0 | 0 | 11 (50.0) | 1 (3.3) | 0 |
| Â | Fluoxetine | 8 (7.0) | 3 (15.0) | 3 (17.6) | 1 (7.1) | 1 (4.5) | 0 | 0 |
Timepoint 2 | Â | n = 112 | n = 20 | n = 17 | n = 14 | n = 22 | n = 27 | n = 12 |
Primary Sedatives [no.(%)] | Promazine | 5 (4.4) | 2 (10.0) | 0 | 1 (7.1) | 1 (4.5) | 1 (3.7) | 0 |
| Â | Temazepam | 4 (3.6) | 0 | 0 | 1 (7.1) | 1 (4.5) | 0 | 2 (16.7) |
| Â | Zopiclone | 4 (3.6) | 1 (5.0) | 0 | 0 | 0 | 2(7.4) | 1 (8.3) |
| Â | Lorazepam | 3 (2.7) | 0 | 0 | 1 (7.1) | 1(4.5) | 1 (3.7) | 0 |
Drugs with sedation as a prominent adverse effect/ | Citalopram | 20 (17.9) | 6 (30.0) | 1 (5.9) | 1 (7.1) | 1 (4.5) | 6 (22.2) | 5 (41.7) |
containing a sedating component [no.(%)] | Trazodone | 15(13.4) | 0 | 0 | 3(21.4) | 11 (50.0) | 1 (3.7) | 0 |
| Â | Quetiapine | 11 (9.8) | 0 | 5 (29.4) | 0 | 5 (22.7) | 1 (3.7) | 0 |
| Â | Fluoxetine | 9 (8.0) | 3 (15.0) | 3 (17.6) | 1 (7.1) | 1 (4.5) | 1 (3.7) | 0 |
Timepoint 3 | Â | n = 105 | n = 19 | n = 16 | n = 14 | n = 21 | n = 25 | n = 10 |
Primary Sedatives [no.(%)] | Promazine | 7 (6.7) | 2 (10.0) | 0 | 1 (7.1) | 1 (4.8) | 2 (8.0) | 0 |
| Â | Temazepam | 3 (2.9) | 0 | 0 | 1 (7.1) | 1 (4.8) | 0 | 1 (8.3) |
| Â | Zopiclone | 3 (2.9) | 0 | 0 | 0 | 0 | 2 (8.0) | 0 |
| Â | Lorazepam | 3 (2.9) | 2 (10.0) | 0 | 1 (7.1) | 1 (4.8) | 1 (4.0) | 0 |
Drugs with sedation as a prominent adverse effect/ | Citalopram | 18 (15.7) | 5 (26.0) | 0 | 2 (14.3) | 1 (4.8) | 5 (20.7) | 5 (50.0) |
containing a sedating component [no.(%)] | Trazodone | 15 (14.3) | 0 | 0 | 3 (21.4) | 10 (47.6) | 1 (4.0) | 1 (10.0) |
| Â | Quetiapine | 9 (8.6) | 0 | 4 (25.0) | 0 | 4 (19.0) | 1 (4.0) | 0 |
| Â | Fluoxetine | 8 (7.6) | 3 (15.8) | 2 (12.5) | 1 (7.1) | 1 (4.8) | 1 (4.0) | 0 |